Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with spirogermanium and 4-demethoxydaunorubicin. There were eight life-threatening complications (mostly hematologic) and two lethal complications (N-MF, hematologic; 4-demethoxydaunorubicin, gastrointestinal). The overall survival ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were associated with poor survival: Poor initial performance status, prior weight loss, presence of liver or subcutaneous metastases.
Ettinger
D S
DS
Johns Hopkins Oncology Center, Baltimore, Maryland ff205.
Finkelstein
D M
DM
Donehower
R C
RC
Chang
A Y
AY
Green
M
M
Blum
R
R
Hahn
R G
RG
Ruckdeschel
J C
JC
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005559:Formamides / Q000009:adverse effects / Q000627:therapeutic use*; D005857:Germanium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D011897:Random Allocation; D012074:Remission Induction; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D005559:Formamides; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium; C002950:methylformamide; D015255:Idarubicin